GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

BL/ - The names of the most important Chief Sustainability Officers of Europe were announced at the Futur/io C ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...

We anticipate that their industry-leading approach will accelerate the discovery of new molecules against high value GSK targets with ... discovery firms are also building their own in-house ...

Building this trust among employees involves ... is aiming to “do the right thing” for wider society. With the new goals, GSK aims to have a net zero impact on climate and a net positive ...

Barbara Salami is the VP of Digital for Commercial at Moderna where she is leads digital transformation for Moderna’s new ...

Natural capital went mainstream in 2024, with biodiversity bonds hitting new highs and record shareholder resolutions on ...

Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...

The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule ...